| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3176 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3320 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3469 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3709 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3917 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3937 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.3986 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.4171 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.4975 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5143 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5294 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5336 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5337 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5357 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5526 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5558 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5568 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5578 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5647 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5712 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5790 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.5902 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6067 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6086 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6156 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6259 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6350 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6430 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6463 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6682 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6743 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6829 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6881 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.6922 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7030 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7128 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7339 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7368 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7383 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7407 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7429 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7604 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.7926 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8102 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8395 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8538 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8616 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8658 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8730 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8782 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8792 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8808 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8858 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8867 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8868 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8886 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.8909 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9023 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9272 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9294 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9406 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9812 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9917 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9925 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9928 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 0.9998 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0002 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0049 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0188 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0269 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0317 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0342 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0356 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0392 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0576 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0632 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.0910 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.1217 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.1407 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.1708 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.1742 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.1895 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2048 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2129 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2327 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2543 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2635 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2800 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.2921 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.3013 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.3124 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.3218 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.3576 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.3951 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4239 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4274 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4793 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4907 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4941 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.4945 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5002 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5424 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5560 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5573 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5583 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5772 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5824 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.5982 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.6488 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.7116 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.7312 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.7659 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 1.8209 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.1478 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.2009 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.2383 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.3654 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.3680 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.7076 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.7772 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 2.9266 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 3.1188 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 3.3055 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 3.4162 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 3.4365 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 3.8162 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 35.0876 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 37.6482 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 39.0450 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 42.3280 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 42.7057 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetate | 50.4028 | scaled units | Low-Dose | +4HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|